Physician profile
John Mapili
NPI 1952317018
$843.72
in general payments reported to CMS, 2019-2025
12 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $349 · 2024: $114 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $251.58 | 2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $112.51 | 2025 | Inspire |
| Abbvie INC. | $103.30 | 2023-2024 | |
| Novo Nordisk INC | $101.56 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.63 | 2023-2024 | Xifaxan |
| Amgen INC. | $63.65 | 2023-2025 | Repatha, Otezla, Evenity |
| Exact Sciences Corporation | $31.00 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $26.80 | 2024 | |
| Janssen Pharmaceuticals, INC | $25.00 | 2023 | Xarelto |
| Nestle Healthcare Nutrition INC. | $23.08 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $19.96 | 2023 | Farxiga |
| Tolmar, INC. | $13.65 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mapili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.